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Abstract
Background: Extracorporeal membrane oxygenation (ECMO) incorporates surgical techniques as adjuncts in the
management of refractory respiratory dysfunction. For many years, its primary application was for support of
neonatal infants in cardiorespiratory failure. As the 2009 H1N1 influenza A pandemic developed, more reports
came in of severe respiratory dysfunction and even death that seemed to be occurring preferentially in younger
adults. Centers with the capability began to use ECMO to salvage these patients.
Results: The H1N1 virus is a subtype of influenza A. The hemagglutinin receptor binding is similar to that of the
seasonal influenza virus, but 2009 H1N1 also binds to a2,3-linked receptors, which are found in the conjunctivae,
distal airways, and alveolar pneumocytes. Influenza viruses elude host immune responses through drift and
shift in the hemagglutinin (HA) and neuraminidase (NA) proteins. The incubation period ranges from 1–7 days.
The majority of patients present with fever and cough, but a broad spectrum of clinical syndromes has been
reported, and laboratory testing remains the mainstay of diagnosis. Most patients recover within a week without
treatment. The H1N1 virus remains largely sensitive to the NA inhibitors but is resistant to the matrix protein-2
inhibitors. Extracorporeal membrane oxygenation provides continuous pulmonary (and sometimes cardiac)
support and minimizes ventilator-induced lung injury. The potential for life-threatening complications is high. In
2009, in the Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) randomized trial
of ECMO, the overall survival rate was 63% in the ECMO group compared with 47% in the control group
(p¼ 0.03). Similar studies have been reported from Australia and New Zealand, Canada, and France.
Conclusions: Supportive management is continued along with ECMO. Antiviral drugs and antimicrobial agents
should be given as appropriate, as should nutritional support. Volume management should be used. Ventilator
settings should be reduced as ECMO support allows, with a goal of reducing airway pressures, ventilator rate,
and FiO2. Complications of ECMO are common. Bleeding, the most common, can result in death, especially if it
occurs intracranially.
Extracorporeal membrane oxygenation (ECMO) in-corporates surgical techniques as adjuncts in the man-
agement of refractory respiratory dysfunction. For many
years, its primary application was for support of neonatal
patients in cardiorespiratory failure. Adult ECMO was prac-
ticed in relatively few centers.
In February 2009, a novel swine-associated (H1N1) influ-
enza virus infection was reported to the U.S. Centers for
Disease Control and Prevention (CDC). The child, whowas in
contact with pigs, recovered uneventfully, and the case was
barely mentioned in the April 17, 2009 edition of the Mor-
bidity and Mortality Weekly Report [1]. However, note was
made the next week of two cases of influenza A (H1N1) virus
infection [2]; both were in children who had no history of
contact with pigs. The two viruses were genetically similar
and substantially different from prior H1N1 strains. The lack
of contact with pigs and the novelty of the strain raised con-
cern about human-to-human transmission of a virus to which
there was no large-scale immunity. By the next week, 64
confirmed cases were reported by the CDC [3], and theWorld
Health Organization (WHO) described 26 confirmed cases
from Mexico. On April 29, 2009, the WHO upgraded its level
of pandemic alert from phase 4 to phase 5, indicating human-
to-human spread in at least two countries in one region [4]. By
May 5, Mexico had identified almost 12,000 suspected cases
with 42 deaths [4]. As the pandemic progressed, more reports
Division of Acute Care Surgery, University of Michigan, Ann Arbor, Michigan.
SURGICAL INFECTIONS
Volume 12, Number 2, 2011
ª Mary Ann Liebert, Inc.
DOI: 10.1089/sur.2010.082
151
came in of severe respiratory failure and even death that
seemed to be occurring preferentially in younger adults.
Centers with the capability began to use ECMO to salvage
these patients. This review discusses the increased use of
ECMO in the context of the 2009H1N1 influenza A pandemic.
H1N1 Virus
The virus at the root of the pandemic, H1N1, is a subtype
of influenza A. Influenza A, along with B and C, are in the
Orthomyxoviridae family. Influenza A viruses have eight
single strands of negative-sense RNA that code for 11 pro-
teins [5]. Influenza A subtyping is based on the antigenicity
of the two major cell-surface glycoproteins: hemagglutinin
(HA) and neuraminidase (NA) (Fig. 1). There are 16 H an-
tigens and 9N antigens. The HA protein promotes binding
of the virus to receptors on the host cell and subsequent
endosomal fusion. Viral release from host cells is facilitated
by the NA protein.
The hemagglutinin receptor binding of H1N1 is similar to
that of seasonal influenza in that H1N1 binds to a2,6-linked
cellular receptors. However, the 2009 strain of H1N1 also
binds to a2,3-linked receptors [6], which are found in the
conjunctivae, distal airways, and alveolar pneumocytes. It is
this binding that is believed to account in part for H1N1’s
higher virulence and ability to infect the lower respiratory
tract [7]. The 2009 H1N1 virus also shows greater replication
in bronchial tissue than does seasonal influenza [8], which
may also contribute to its ability to cause severe viral pneu-
monitis. Animal studies show that inoculation of the respi-
ratory tract can result in viral invasion of the gastrointestinal
(GI) tract mucosa [9].
Drift vs. Shift
Influenza viruses elude host immune responses through
drift and shift in theHA andNAproteins [10]. ‘‘Drift’’ refers to
the frequent minor changes in the antigens. These drifts are
associated with annual changes in seasonal influenza. ‘‘Shift’’
refers to the introduction of an influenza A virus subtype to
which the population has no immunity. Shifts are believed to
be facilitated by the virus’ ability to infect a wide variety of
hosts [10]. Antigenic shifts in the HA subtypes are associated
with pandemics, three of which occurred in the 20th Century
[11]. Prior to 1957, H1N1 viruses were the dominant influ-
enza A viruses, until replacement by the H2N2 ‘‘Asian’’ strain.
These prior H1N1 strains may have resulted in cross-
protective antibodies against 2009 H1N1 for those alive prior
to 1957 [12,13].
Illness
Clinical manifestations
The incubation period of the H1N1 virus differs widely
[14–18], but in general ranges from 1–7 days, with most
symptomatic cases occurring within 1–5 days after exposure.
The majority of patients present with fever and cough
[19,20], but a broad spectrum of clinical syndromes has been
reported, from asymptomatic illness to fulminant viral
pneumonia [14]. Gastrointestinal symptoms are more com-
mon with 2009 H1N1 than with seasonal influenza [21,22],
which may reflect the virus’ ability to attack the mucosa of
the GI tract [9].
Because of the wide range and non-specificity of the
symptoms, laboratory testing remains the mainstay of diag-
nosis of H1N1. The usual method is by nasopharyngeal swab
FIG. 1. Structural diagram of influenza A virus. H¼hemagglutinin; M¼matrix; N¼ neuraminidase; NP¼nucleoprotein;
NS¼nonstructural; PA¼ acidic polymerase; PB¼ basic polymase. Reprinted with permission from Kaiser J. A one-size-fits-
all flu vaccine. Science 2006;312:380–382.
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or aspirate taken early after the onset of symptoms or bron-
choscopic aspirates in those requiring intubation. The most
accurate test is one that detects viral RNA by conventional or
real-time reverse transcriptase polymerase chain reaction (RT-
PCR) [23]. Multiple studies demonstrate fewer false-negative
results from bronchoscopic specimens [22–25], so these
should be used preferentially when available. A study by
Blyth et al. showed that almost 20% of patients with a positive
bronchoscopic aspirate had a negative result from an upper
respiratory sample [25]. Consequently, a single negative
upper respiratory sample does not rule out H1N1, and
treatment should not be stopped on this basis. Falsely nega-
tive lower respiratory samples have also been reported, so
repeat bronchoscopic sampling in the setting of clinical sus-
picion is also appropriate with these patients [14].
Treatment
Most patients will recover within a week even without
treatment. Patients with severe illness (Table 1), who deteri-
orate, or who have risk factors for complicated illness (Table
2) should be treated [26]. The virus remains largely sensitive
to theNA inhibitors oseltamivir and zanamivir. However, it is
resistant to the matrix protein-2 inhibitors amantadine and
rimantadine [21,27]. Clinicians should consider using higher
doses of oseltamivir for a longer period for patients who have
severe disease or who are deteriorating [28,29].
There are reports of isolates of oseltamivir-resistant H1N1,
especially in patients with immunosuppression who received
prolonged courses [30,31] or who failed post-exposure pro-
phylaxis with oseltamivir [32]. These patients may still re-
cover without complications, but if they require treatment,
zanamivir should be used [33]. There have been no reports of
zanamivir resistance in 2009 H1N1 influenza A.
Attack rates
The attack rate is the cumulative incidence of infection in a
population during an epidemic. Reported attack rates for
H1N1 have ranged from 100 to 10,000 per 100,000 population
[19,34,35]. However, in one residential school, the attack rate
for influenza-like illness was 71% and for confirmed H1N1
was 42% [36], showing the dramatic impact that close living
quarters can have on transmission of the virus. Estimated
rates of hospitalization for those who contract the virus range
from 0.3% to 9%,with case fatality rates ranging from 0.02% to
0.5% (Fig. 2) [21,34,37].
Risk factors
Risk factors for contracting the disease appear to be
younger age, pregnancy, contact with someone with H1N1
infection or influenza-like illness, and belonging to a disad-
vantaged group [14,19,38]. Pregnant women and obese indi-
viduals are over-represented in the population of patients
infected with H1N1 who require hospitalization or who suc-
cumb to the disease [39–45]. A number of other patient
characteristics also are associated with severe disease or
complications (Table 2) [28]. A subset of patients become
critically ill and develop acute respiratory distress syndrome
(ARDS) characterized by severe hypoxemia. In cases of re-
spiratory failure refractory to conventional treatment, high
ventilator settings, alternative ventilator modes (such as bi-
level ventilation and high-frequency oscillatory ventilation),
and other rescue modalities, such as prone positioning, nitric
oxide, or ECMO may be used.
Extracorporeal Membrane Oxygenation
Methods of ECMO support
Components of the ECMO circuit are the pump, the oxy-
genator, and vascular access to the patient’s circulatory sys-
tem. There are two forms of ECMO: Venovenous (VV) and
venoarterial (VA). Venovenous ECMO provides only oxy-
genation, whereas VA ECMO provides circulatory support as
well.
In VV ECMO, blood drains out of a large-bore venous
cannula, passes through the membrane oxygenator for gas
exchange, then is returned to the venous system via a cannula
placed close to the right atrium. A multiple cannula system
such as this usually drains from one or two cannulas in the
femoral veins and returns blood to the vena cava via a cannula
in the right internal jugular vein. A dual-lumen cannula is also
available. Insertion is into the right internal jugular vein, and
the cannula drains from both the superior and the inferior
vena cava. The blood is returned to a port that is aimed at the
right atrium under ultrasound guidance.
Venoarterial ECMO also drains from the femoral vein but
usually returns blood to the femoral artery. The action of the
pump in the circuit provides cardiac support. Compared with
VV, VA ECMO has more potential complications, including
ischemia from arterial cannulation. ‘‘North–South syndrome’’
occurs when some left ventricle function is preserved. The
ventricular pumping action directs the relatively deoxygen-
ated blood that has passed through the native lung into the
head and upper extremities while preventing retrograde flow
into the proximal aorta of well-oxygenated blood from the
ECMO circuit. Therefore, the brain, heart, and upper ex-
tremities may be hypoxemic, whereas the lower extremities
are well oxygenated.
Characteristics of procedure
Extracorporeal membrane oxygenation provides continu-
ous pulmonary (and sometimes cardiac) support on a longer-
term basis than the cardiopulmonary bypass machines used
in the operating room. This period can last fromdays toweeks
and allows minimization of ventilator-induced lung injury
while the lungs heal. Extracorporeal membrane oxygenation
is a complex treatment that requires a dedicated team that
includes surgical support or supervision. The potential for
Table 1. Warning Signs of More Severe Disease
Dyspnea, either during physical activity or while resting
Cyanosis
Bloody or colored sputum
Chest pain
Altered mental status
High fever that persists beyond three days
Hypotension
In children, danger signs include tachypnea or dyspnea,
drowsiness, and little or no desire to play
From Reference 26.
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life-threatening complications is high; therefore, its use is re-
served for patients whose hypoxia confers a substantial risk of
death.
The efficacy of ECMO for neonatal [46–48] and pediatric
[49,50] patients has been well established, with an overall
survival rate to discharge of 64% in a large voluntary database
(Extracorporeal Membrane Oxygenation Organization; un-
published data]. However, initial trials of ECMO in adults
[51,52] had disappointing results, and adult ECMO fell by the
wayside except in a few centers. However, the publication of
the Conventional Ventilation or ECMO for Severe Adult Re-
spiratory Failure (CESAR) trial [53] and concurrent reports of
the use of ECMO for the sickest patients during the 2009
H1N1 pandemic re-ignited interest in adult ECMO for respi-
ratory failure.
History
Heart–lung machines were used in surgery many years
before ECMO became practical. The problem was that the
oxygenators of the time involved direct contact of air with the
bloodstream, and resulting cell damage limited use to 4 h or
less. Longer use required the development of a membrane
oxygenator [54]. Once that device was available, ECMO was
successful in 1971 on an adult traumapatient inCaliforniawho
developed ARDS [55]. However, a multicenter randomized
controlled trial in 1979 showed no benefit to ECMO vs. con-
ventional ventilation for adult ARDS [51]. Problems identified
with the study included selection bias that excluded both the
least ill and the sickest patients; failure to use ‘‘rest settings’’ on
the ventilator for some patients in the ECMO arm; absence of
prior ECMO experience in some centers; and a biased patient
pool attributable to the influenza epidemic of 1976 [56].
Two subsequent studies looked at extracorporeal CO2 re-
moval only. In 1986, Gattinoni et al. reported a series of 43
patients who had low-flow extracorporeal CO2 removal
combinedwith low-frequency ‘‘rest ventilation’’ [57]. Survival
in this cohort was 48.8%, which was impressive for this era.
However, in 1994, Morris et al. reported a randomized con-
trolled trial of CO2 removal compared with inverse ratio
ventilation, which was popular at the time [52]. This was a
small trial (n¼ 40), and no difference was found in survival
(42% for the control group and 33% for the extracorporeal
group). This study has been criticized for its small size, failure
to achieve lung rest in the extracorporeal group, and the high
blood loss in the extracorporeal group [58]. Both studies have
been criticized for focusing on CO2 removal, as hypercarbia
generally is well-tolerated in ARDS.
With these studies, interest in ECMO for respiratory dis-
ease in adults waned in the 1980s and 1990s, whereas research
continued in pediatric and cardiac populations. In contrast to
the original studies, newer data reflect advances in intensive
care unit (ICU) support, ventilator management strategies,
non-ventilatory ARDS care, and ECMO technology that have
occurred over the past 20 years.
A retrospective review of the Extracorporeal Life Support
Organization (ELSO) data from 1986–2006 examined the re-
sults for 1,473 adult patients who received ECMO for severe
respiratory dysfunction [59]. The overall survival rate to dis-
Table 2. Risk Factors for Complications of or Severe Illness with 2009 H1N1 Virus Infection
Risk factor Examples and comments
Age <5 years Children <2 years of age are at even higher risk
Pregnancy Higher risk of hospitalization than non-pregnant women; risk
is highest in the third trimester.
Chronic pulmonary disease (any age) Asthma, chronic obstructive pulmonary disease, cystic fibrosis
Chronic cardiac disease (any age) Congestive heart failure
Other chronic disease Renal, hepatic disorders
Certain neurologic conditions Includes neuromuscular, neurocognitive, and seizure disorders
but not autism spectrum disorders
Hemoglobinopathies or
immunosuppression
Includes primary immunosuppressive conditions such as human
immunodeficiency virus infection and secondary conditions such
as immunosuppressive medication or malignancy
Chronic aspirin therapy in children Risk of Reye syndrome
Age 65 years or older Lower rates of infection but higher case fatality rate
Obesity Body mass index of 30 kg/m2; higher risk with morbid obesity
(body mass index of 40 kg/m2)
Disadvantaged or indigenous
populations
Adapted from Reference 14.
FIG. 2. Estimated pandemic disease burden. Reprinted
from Dawood FS, Hope KG, Durrheim DN, et al. Estimating
the disease burden of pandemic (H1N1) 2009 virus infection
in Hunter New England, Northern New South Wales, Aus-
tralia, 2009. PLoS One 2010;5:e9880.
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charge was 50%; however, patient treatment was not ran-
domized, and there was no control group. The study authors
found that increasing age, pre-ECMO arterial blood
pH< 7.18, longer duration of pre-ECMO mechanical venti-
lation, lower patient weight, Asian background, and compli-
cations of ECMOwere associated with a poorer survival rate.
Venovenous ECMO was associated with better survival than
VA ECMO. As noted, this technique provides cardiac support
in addition to pulmonary support, so differences in underly-
ing disease in the patients placed on VA and those given VV
ECMO may account for this finding. Acute respiratory dys-
function and asthma conferred a survival benefit compared
with patients whose diagnosis was listed as ARDS. Ap-
proximately 9% of patients sustained radiographic evidence
of cerebral infarction, hemorrhage, or brain death.
In 2009, the results of the CESAR trial were published [53].
This was a multicenter, randomized, controlled trial con-
ducted in the United Kingdom from 2001 through 2006. Pa-
tients with severe (Murray score 3 (Table 3) or pH< 7.20),
but potentially reversible, ARDS were randomized to either
conventional care at one of the participating 68 tertiary care
centers or transfer to a single center that is the sole provider of
adult ECMO in the U.K. Whereas patients at the ECMO center
were treated according to a strict protocol, the ‘‘pragmatic’’
nature of the trial meant that care at the other 68 centers was
not standardized. Patients were excluded if they had been on
high ventilatory pressures or high inspired oxygen concen-
trations formore than seven days prior to trial entry, had signs
of intracranial bleeding, or had contraindications to the he-
parinization necessary for ECMOor continuation of treatment.
Of the 90 patients randomized to the ECMO arm, 75% ul-
timately received ECMO. Of these, 63% survived. Of the pa-
tients who did not receive ECMO, three died prior to transfer,
two died during transfer, and one developed a contraindica-
tion to heparin. The other 16 patients improved with con-
ventional management at the ECMO center, and 82% of these
survived to hospital discharge. The overall survival rate was
63% in the ECMO group compared with 50% in the control
group. This difference approached statistical significance
(p¼ 0.07). When the endpoint of death or severe disability
was used, ECMO conferred a benefit (63% vs. 47%; relative
risk [RR], 0.69; 95% confidence interval [CI] 0.05–0.97). The
mean time of ventilation prior to entry into the study was
similar: 35 h for the ECMO arm and 37h for the control arm.
Mean Murray scores were high at 3.5 and 3.4, respectively.
Median hospital days and critical care days were longer in the
ECMO arm. Economic analysis showed that patients referred
to the ECMO center gained 0.03 quality-adjusted life-years
(QALYs) at six-month follow up at a cost of about $32,000 per
QALY.
The study authors acknowledge in their discussion that the
benefit may come from referral to a center with extensive
experience treating ARDS rather than from ECMO itself.
However, three quarters of the patients referred to the center
ultimately required ECMO despite presumably optimal
management. This suggests that ECMO may still have a role
in severe ARDS not responsive to optimal management.
Extracorporeal membrane oxygenation and the 2009
H1N1 Influenza A pandemic
At the same time the CESAR trial was published, the 2009
H1N1 influenza pandemic was raging. Two months after CE-
SAR’s publication, 15 centers that provide ECMO in Australia
and New Zealand published an observational study of the use
of the technique for patients with H1N1-associated pulmonary
failure [60]. Of the patients with 2009 H1N1 in the 15 centers
who required mechanical ventilation, 68 (34%) were placed on
ECMO. Only the 61 patients on ECMO who had confirmed
influenza A respiratory failure were included in the analysis.
The most common co-morbidities in the group requiring
ECMO were obesity (body mass index >30kg/m2) (50%),
asthma (28%), and diabetes (15%). However, the rates of these
co-morbidities were not statistically different from those in the
group that did not receive ECMO. The overall incidence of
pregnant patients was 15%. The ECMO group had a lower
median age (36 years vs. 44 years), were more likely to have
required vasopressor therapy on admission to the ICU, and
had longer durations of mechanical ventilation and ICU stays,
but not hospital stays. The mortality rate in the ECMO group
was an impressively low 21% (all deaths occurred in the ICU),
with an ICUmortality rate of 9% in the comparison group and
an overall mortality rate of 13%. The ICU death rate was sig-
nificantly lower in the comparison group, but the overall
mortality rate approached statistical significance difference
(p¼ 0.06). Unlike the U.K. study, the investigators in Australia
and New Zealand had the capacity to place patients on ECMO
at a referring hospital and transport patients on ECMO. More
than one–half (38) of the 68 ECMO patients were placed on
ECMO for transport.
Because the 15 centers are the only ones in Australia and
New Zealand that provide ECMO, the authors were able to
calculate a population-based ECMOuse rate of 2.6 per million
population during this time. By comparison, the previous
influenza season had resulted in only four patients requiring
ECMO, for a rate of 0.15/1,000,000. Clearly, ECMO played a
Table 3. Elements and Values of the Murray Score. Average of the Four Elements Is Score
Score
Element 0 1 2 3 4
PaO2: FiO2 300 225–299 175–224 100–174 <100
Number of quadrants on chest radiograph
with infiltrates
0 1 2 3 4
PEEP (cm H2O) 5 6–8 9–11 12–14 15
Compliance (mL/cm H2O) 80 60–79 40–59 20–39 19
PEEP, positive end-expiratory pressure.
From Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis
1988;138:720–723.
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more important significant role in the treatment of pandemic
H1N1 influenza than in seasonal influenza.
Canadian researchers reported on the experience of 34
ICUs across the country [61]. The centers admitted 168 pa-
tients with confirmed H1N1 influenza infection. Of these, 6
(4%) required ECMO. These patients were younger (22 vs. 32
years of age) and were more likely to have received therapies
such as high-frequency ventilation (three patients), inhaled
nitric oxide (six patients), prone ventilation (two patients),
and neuromuscular blockade (six patients). They were less
likely to have received corticosteroids (33% vs. 51%). Two
patients were placed on VA ECMO, the rest on VV. The
mortality rate was 33%, compared with 14% in the non-
ECMO group. Both patients died while on ECMO. As in the
CESAR trial, patients who survived to decannulation also
survived to hospital discharge.
More recently, researchers in Marseille, France presented
their single-center experience [62] with 22 institutional criteria
for ECMO. One patient died before ECMO could be insti-
tuted. Six patients were placed on VV ECMO and the other
three on VA ECMO. Six patients required cannulation at the
referring facility and transport on ECMO. Five patients (56%)
died in both the ECMO and non-ECMO ARDS groups. Other
investigators have reported single cases and case series of
their experiences with ECMO for H1N1 severe ARDS [63–71].
Consideration for referral to an ECMO center
If ECMO is to be used for an adult with severe ARDS as a
result of H1N1, referral to an ECMO center should be con-
sidered if the patient is not responding to conventional
management and has a mortality risk estimated to exceed
50%. Adult respiratory distress syndrome in patients with
H1N1 infection can progress rapidly, and transportation on
ECMO is available in only a fewplaces in theworld. Therefore, a
balance must be struck between referring too early and over-
whelming the ECMO center with patients who will not require
ECMO vs. referring too late, when the patient is too sick to
survive transport. As the pandemic wanes, the first consider-
ation becomes less important than the second. Referral criteria
derived from the CESAR trial [53] are patients 65 years of age or
younger and a Murray score of 3 (see Table 3) or uncompen-
sated hypercarbia with pH< 7.20. Contraindications to ECMO
include irreversible pulmonary disease, terminal disease, con-
traindication to full anticoagulation, and refusal to receive blood
products. Individual ECMO centers may have additional crite-
ria such as a maximum acceptable body mass index because of
inability to achieve sufficient oxygen delivery for the body size.
Relative contraindications to ECMO (because of historically
poor survival rates) include mechanical ventilation for more
than 10 days or high-pressure mechanical ventilation for more
than seven days. Early telephone contact with the ECMO center
can help identify appropriate candidates for transfer.
Management on ECMO
Supportive management is continued after initiation of
ECMO. Antiviral drugs [72] and antimicrobial agents should
be instituted or continued as appropriate. Nutritional support,
preferably by enteral means, should be continued. Volume
management, which may require hemofiltration, should be
used to achieve the patient’s appropriate dryweight. Ventilator
settings should be reduced as ECMO support allows, with a
goal of reducing airway pressures, ventilator rate, and per-
centage of inspired oxygen (FiO2). Oxymetric measurement of
the venous limb of the circuit can be used to monitor the ade-
quacy of support. Systemic anticoagulation, usually with
heparin, is administered to prevent circuit clotting. Hepar-
inization is monitored by bedside measurement of activated
clotting time or partial thromboplastin time. Continuous renal
replacement therapy commonly is needed. It is preferable to
run this via separate venous access, but some circuits can ac-
commodate a filter if separate access is impossible.
Complications
Complications of ECMOare common and prevent its wider
use for less moribund patients. Bleeding is the most common
complication and can result in death, especially if it occurs
intracranially. Avoidance of bleeding is of primary impor-
tance. Invasive procedures should be limited, bronchoscopy
performed atraumatically, and cautery used extensively for
any procedure that must be performed. If bleeding does
occur, it can be managed by decreasing or temporarily stop-
ping heparin (with the attendant risks) and infusing platelets
and clotting factors. Pulmonary hemorrhage may necessitate
frequent bronchoscopy to clear the airways. Intracerebral
hemorrhage or infarction occurs in 10–15% of ARDS patients
on ECMO [49]. In Australia and New Zealand, 43% of the
deaths on ECMO were related to intracranial hemorrhage
[60]. Because of the critical condition of these patients and the
inability to stop anticoagulation for any significant period of
time, intracranial hemorrhage usually is fatal.
During cannulation, fatal vascular perforation can occur
because of the size and stiffness of the cannulas. For this reason,
if a surgeon is not personally performing the cannulation, one
with vascular repair capabilities should be at hand. Hemolysis
generally does not occur with modern ECMO circuits unless
there is a problem in the circuit or the patient. The plasma
free hemoglobin concentration should be monitored daily.
Values> 10mg/dL should prompt an investigation into the
cause and correction thereof. Thromboembolic disease has
been reported after decannulation after ECMO for H1N1-
associated respiratory failure [71]. For this reason, consider-
ation should be given to continuation of full anticoagulation
after cannula removal. If the patient had a femoral venous
cannula in place, consideration should be given to placement of
an inferior vena cava filter at the time of cannula removal.
The 2009 H1N1 influenza A pandemic has produced a
surprising number of relatively young patients with severe
respiratory dysfunction. Because these patients are young,
seldom have life-limiting co-morbidities, and have a revers-
ible disease, they can be considered for salvage therapy with
ECMO when conventional therapies fail. Because of the in-
tensive knowledge, personnel, and equipment needs, an
ECMO program is not to be undertaken lightly.
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